Liver and Bile

J Gastroenterol Hepatol. 2023;38(4):648–55

Cho SH, Song TJ, Park JS, Yoon JH, Yang MJ, Yoon SB, Lee JM, Lee YN, Kim SH, Choi EK, Park SW, Oh D, Park DH, Lee SS, Seo DW, Lee SK, Kim MH

Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: A multicenter cohort study

Background and aims: Immunoglobulin G4-related sclerosing cholangitis (IgG4-SC) is considered a biliary manifestation of IgG4-related diseases. However, there has been a controversy on the clinical outcomes according to the location of the involved bile duct. The authors therefore compared the clinical outcomes and long-term prognosis of IgG4-SC with proximal bile duct involvement (proximal IgG4-SC) and IgG4-SC with distal bile duct involvement (distal IgG4-SC).
Methods: They reviewed the data of patients with IgG4-SC that were prospectively collected at 10 tertiary centers between March 2002 and October 2020. Clinical manifestations, outcomes, association with autoimmune pancreatitis (AIP), steroid-responsiveness, and relapse of IgG4-SC were evaluated.
Results: A total of 148 patients (proximal IgG4-SC, n = 59; distal IgG4-SC, n = 89) were analyzed. The median age was 65 years (interquartile range [IQR], 56.25–71), and 86% were male. The 2 groups were similar in terms of jaundice at initial presentation (51% vs. 65%; p = 0.082) and presence of elevated serum IgG4 (66% vs. 70%; p = 0.649). The 2 groups showed significant differences in terms of steroid-responsiveness (91% vs. 100%; p = 0.008), association with AIP (75% vs. 99%; p = 0.001), and occurrence of liver cirrhosis (9% vs. 1%; p = 0.034). During a median follow-up of 64 months (IQR, 21.9–84.7), the cumulative relapse-free survival was significantly different between the 2 groups (67% vs. 79% at 5 years; p = 0.035).

Conclusions: Relapse of immunoglobulin G4-related sclerosing cholangitis (IgG4-SC) frequently occurred during follow-up. Proximal IgG4-SC and distal IgG4-SC had different long-term outcomes in terms of steroid-responsiveness, occurrence of liver cirrhosis, and recurrence. It may be advantageous to determine the therapeutic and follow-up strategies according to the location of bile duct involvement.

Dr. Dr. T.J. Song, Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea,
E-Mail: drsong@amc.seoul.kr

DOI: 10.1111/jgh.16136

Back to overview

this could be of interest:

Liver and Bile

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated

J Hepatol. 2023;78(5):989–97

Liver and Bile

Model to predict major complications following liver resection for HCC in patients with metabolic syndrome

Hepatology. 2023;77(5):1527–39

Berardi G, Ratti F, Sposito C, Nebbia M, D’Souza DM, Pascual F, Dogeas E, Tohme S, D’Amico FE, Alessandris R, Simonelli I, Del Basso C, Russolillo N, Moro A, Fiorentini G, Serenari M, Rotellar F, Zimmitti G, Famularo S, Ivanics T, Hoffman D, Onkendi E, Essaji Y, Lopez Ben S, Caula C, Rompianesi G, Chopra A, Abu Hilal M, Torzilli G, Sapisochin G, Corvera C, Alseidi A, Helton S, Troisi RI, Simo K, Conrad C, Cescon M, Cleary S, Kwon CHD, Ferrero A, Ettorre GM, Cillo U, Geller D, Cherqui D, Serrano PE, Ferrone C, Mazzaferro V, Aldrighetti L, Kingham TP

Go to article